Gary Abromovitz
Nessuna posizione attualmente
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Vincent Carson | M | 64 | 23 anni | |
Timothy Meeker | M | 77 | 20 anni | |
Thurman Case | M | 67 | 7 anni | |
Darren Woody | M | 64 | 20 anni | |
Beryl Raff | F | 73 | 10 anni | |
Krista Berry | F | 59 | 7 anni | |
Tessa Judge | F | 40 | 9 anni | |
Tabata Gomez | M | 43 | 2 anni | |
Elena Otero | F | 59 | 2 anni | |
Noel Geoffroy | F | 52 | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Gerald J. Rubin | M | 80 | 46 anni | |
Robert D. Spear | M | - | - | |
Julien Mininberg | M | 59 | 10 anni | |
Michael Cafaro | M | - | - | |
John R. Boomer | M | 62 | - | |
Matthew Osberg | M | 48 | 7 anni | |
Thomas J. Benson | M | 67 | 13 anni | |
Thomas J. Stegmann | M | 77 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | 11 anni |
Brian Grass | M | 54 | 15 anni | |
John B. Butterworth | M | 72 | - | |
William F. Susetka | M | 70 | 11 anni | |
Stanlee N. Rubin | F | 80 | 43 anni | |
Richard J. Oppenheim | M | - | - | |
Alexander Davern | M | 57 | - | |
Adolpho R. Telles | M | 74 | - | |
Daniel C. Montano | M | 75 | 23 anni | |
Leah Bailey | F | 68 | 2 anni | |
Robert Ballard | M | - | 2 anni | |
Connie Hallquist | F | - | - | |
Frédéric M. Chanson | M | 69 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
Pedro T. Contreras | M | - | - | |
James C. Swaim | M | 71 | 1 anni | |
Bart Plaumann | M | - | - | |
Christopher Carameros | M | 70 | 13 anni | |
John H. Conklin | M | - | 4 anni | |
Mike Norris | M | - |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
Alexander Gene Montano | M | - |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
Robert Levin | M | 92 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
Thomas L. Ingram | M | 69 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | - |
Richard R. Dwyer | M | - | - | |
Byron H. Rubin | M | 74 | 29 anni | |
Joong-Ki Baik | M | 69 |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | 9 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Bermuda | 35 | 83.33% |
Stati Uniti | 7 | 16.67% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Gary Abromovitz
- Contatti personali